Mapping the Severity of Phenylalanine Hydroxylase Deficiency
Journal of Inherited Metabolic Disease · 2026
DOI: 10.1002/jimd.70215 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von S Haitjema und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen, Groningen, the Netherla…. Hauptthemen laut MEDLINE: Phenylketonurias, Phenylalanine Hydroxylase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Since the 1960s, phenylalanine hydroxylase (PAH) deficiency can be detected via newborn screening, allowing early start of treatment to prevent severe intellectual disability. Precise determination of PAH deficiency severity continues to be hampered by several factors. Nevertheless, as therapeutic options broaden, precise determination of PAH deficiency severity becomes critical to inform individualized treatment selection. Although various methods (hepatic PAH activity, pretreatment phenylalanine (Phe) levels, Phe loading test, Phe tolerance, in vitro expression analysis, tracer studies, prediction models) have been used to assess and/or classify PAH deficiency, all of them still report inconsistencies in the correlation between genotype and biochemical phenotype. Establishing the genotype–phenotype correlation for different genotypes is complicated by the enormous genetic heterogeneity within the PAH gene. Furthermore, variability in the terminology applied to different phenotype strata further complicates interpretation. Here, we aim to summarize the methods that have been described in the literature to assess the classification of PAH deficiency and propose terminology to describe phenotype levels as a crucial step to overcome these issues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands.
- Laboratory of Metabolic Diseases, Central Laboratory of Clinical Chemistry, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands.
- Medical University Innsbruck, Institute of Human Genetics, Innsbruck, Austria.
ORCID-Profile: S Haitjema, C M A Lubout, J Zschocke, F J van Spronsen
Zitieren
APA
Haitjema, S., van Steenis, E. M., Lubout, C. M. A., Heiner-Fokkema, M. R., Zschocke, J., & van Spronsen, F. J. (2026). Mapping the Severity of Phenylalanine Hydroxylase Deficiency. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70215
Vancouver
Haitjema S, van Steenis EM, Lubout CMA, Heiner-Fokkema MR, Zschocke J, van Spronsen FJ. Mapping the Severity of Phenylalanine Hydroxylase Deficiency. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70215
BibTeX
@article{Haitjema2026,
author = {Haitjema, S and van Steenis, E M and Lubout, C M A and Heiner-Fokkema, M R and Zschocke, J and van Spronsen, F J},
title = {Mapping the Severity of Phenylalanine Hydroxylase Deficiency},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
doi = {10.1002/jimd.70215}
}
EUVIMED